Cargando…
A Glycosaminoglycan Extract from Portunus pelagicus Inhibits BACE1, the β Secretase Implicated in Alzheimer’s Disease
Therapeutic options for Alzheimer’s disease, the most common form of dementia, are currently restricted to palliative treatments. The glycosaminoglycan heparin, widely used as a clinical anticoagulant, has previously been shown to inhibit the Alzheimer’s disease-relevant β-secretase 1 (BACE1). Despi...
Autores principales: | Mycroft-West, Courtney J., Cooper, Lynsay C., Devlin, Anthony J., Procter, Patricia, Guimond, Scott E., Guerrini, Marco, Fernig, David G., Lima, Marcelo A., Yates, Edwin A., Skidmore, Mark A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562973/ https://www.ncbi.nlm.nih.gov/pubmed/31100859 http://dx.doi.org/10.3390/md17050293 |
Ejemplares similares
-
Glycosaminoglycans from Litopenaeus vannamei Inhibit the Alzheimer’s Disease β Secretase, BACE1
por: Mycroft-West, Courtney J., et al.
Publicado: (2021) -
Inhibition of BACE1, the β-secretase implicated in Alzheimer’s disease, by a chondroitin sulfate extract from Sardina pilchardus
por: Mycroft-West, Courtney J., et al.
Publicado: (2020) -
Tools for the Quality Control of Pharmaceutical Heparin
por: Devlin, Anthony, et al.
Publicado: (2019) -
Moult cycle specific differential gene expression profiling of the crab Portunus pelagicus
por: Kuballa, Anna V, et al.
Publicado: (2011) -
A semi-synthetic glycosaminoglycan analogue inhibits and reverses Plasmodium falciparum cytoadherence
por: Skidmore, Mark A., et al.
Publicado: (2017)